Mineralocorticoid Receptor Antagonists for Treatment of Hypertension and Heart Failure

about

Mineralocorticoid Receptor Antagonists for Treatment of Hypertension and Heart Failure

Item

http://www.wikidata.org/entity/Q28066549

description

2015 nî lūn-bûn

@nan

2015 թուականին հրատարակուած գիտական յօդուած

@hyw

2015 թվականին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Mineralocorticoid Receptor Antagonists for Treatment of Hypertension and Heart Failure

@ast

Mineralocorticoid Receptor Antagonists for Treatment of Hypertension and Heart Failure

@en

Mineralocorticoid Receptor Antagonists for Treatment of Hypertension and Heart Failure

@nl

type

Item

label

Mineralocorticoid Receptor Antagonists for Treatment of Hypertension and Heart Failure

@ast

Mineralocorticoid Receptor Antagonists for Treatment of Hypertension and Heart Failure

@en

Mineralocorticoid Receptor Antagonists for Treatment of Hypertension and Heart Failure

@nl

prefLabel

Mineralocorticoid Receptor Antagonists for Treatment of Hypertension and Heart Failure

@ast

Mineralocorticoid Receptor Antagonists for Treatment of Hypertension and Heart Failure

@en

Mineralocorticoid Receptor Antagonists for Treatment of Hypertension and Heart Failure

@nl

P1476

Mineralocorticoid Receptor Antagonists for Treatment of Hypertension and Heart Failure

@en

P2093

Domenic A. Sica

http://www.w3.org/2001/XMLSchema#string

P2860

2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

Diuretics: a review and update

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

Aldosterone antagonists in hypertension and heart failure.

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.

The 45-year story of the development of an anti-aldosterone more specific than spironolactone.

Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure.

Spironolactone for heart failure with preserved ejection fraction.

Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis.

Aldosterone in congestive heart failure.

P304

235-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.14797/MDCJ-11-4-235

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27057293

http://www.w3.org/2001/XMLSchema#string

P921

heart failure

arterial hypertension

mineralocorticoid

P932

4814010

http://www.w3.org/2001/XMLSchema#string